Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer

Area of Science:

• Molecular Biology
• Cancer Research
• Biochemistry

Background:

• Poly(ADP‑ribose) polymerase (PARP) inhibitors are increasingly used in cancer therapy, necessitating research into resistance mechanisms.
• CHFR, an E3 ubiquitin ligase, and ALC1, an oncogene involved in breast cancer metastasis, play roles in DNA damage response.
• The mechanism by which PARylated PARP1 activates ALC1 at DNA damage sites is not fully understood.

Purpose of the Study:

• To elucidate the mechanism of ALC1 regulation by CHFR and its dependence on PARylation.
• To investigate the impact of PARP1/2 inhibitors on ALC1 ubiquitination, degradation, and expression.
• To understand how these interactions affect the efficacy of DNA damage response drugs in breast cancer.

Main Methods:

• Mass spectrometry, western blot analysis, and immunoprecipitation to confirm CHFR-ALC1 interaction.
• Generation of deletion mutants to map interaction domains.
• Assessment of ALC1 ubiquitination, half-life, and transcriptional levels in the presence and absence of PARP1/2 inhibitors.

Main Results:

• CHFR interacts with ALC1, requiring specific domains (CHFR PBZ, ALC1 PMD and MACRO) and PARylation.
• CHFR-mediated ubiquitination of ALC1 leads to its degradation.
• PARP1/2 inhibitors reduce ALC1 ubiquitination, causing ALC1 accumulation and increased expression.

Conclusions:

• PARP1/2 inhibitors decrease ALC1 ubiquitination by CHFR, leading to ALC1 accumulation.
• This accumulation of ALC1 may compromise the therapeutic effects of DNA damage response drugs in breast cancer.
• Understanding this mechanism is crucial for optimizing PARP inhibitor-based cancer therapies.